• Chart
  • F&O
  • Rating
  • Financials
  • Technicals
  • Volume
  • Result
  • Synopsis
  • Corp Action
  • MF Shareholding
  • Similar Stocks
  • FAQs
    1. Home
    2. Stocks
    3. Cipla Share Price

    Cipla Share PriceCipla

    Large Cap 46.2k Result
    ₹1,222.8
    17.6 (1.46%)
    As on 07 December, 2023 | 19:24 BSE: 500087 NSE: CIPLAISIN: INE059A01026

    Cipla Performance

    Day Range

    • Low 1,197.00
    • High 1,225.00
    ₹ 1,222.8

    52 Week Range

    • Low 852.00
    • High 1,283.55
    ₹ 1,222.8
    • Open Price1,206.00
    • Previous Close1,205.20
    • Volume1269290

    Start SIP in Cipla

    Start SIP

    Cipla Share Price

    • Over 1 Month 0.52%
    • Over 3 Month -2.12%
    • Over 6 Month 27.32%
    • Over 1 Year 10.63%

    Cipla Key Statistics

    P/E Ratio 28.6
    PEG Ratio 0.8
    Market Cap Cr 98,723
    Price to Book Ratio 4.2
    EPS 31.6
    Dividend 0.7
    Relative Strength Index 52.11
    Money Flow Index 52.42
    MACD Signal 3.03
    Average True Range 23.7

    Cipla F&O

    Cipla Futures
    Cipla Option Chain

    Cipla Investment Rating

    • Master Rating:

    • Cipla has an operating revenue of Rs. 24,556.43 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 18% is great, ROE of 11% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 12% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. It has recently broken out of a base in its weekly chart and is trading around -5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 92 which is a GREAT score indicating consistency in earnings, a RS Rating of 44 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A which is evident from recent demand for the stock, Group Rank of 68 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.

    EPS Strength

    Price Strength

    Buyer Demand

    Group Rank

    Cipla Financials
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 4,1673,8583,4863,5413,7463,0702,882
    Operating Expenses Qtr Cr 3,2863,1143,0942,9613,0902,3002,559
    Operating Profit Qtr Cr 1,3791,2058009381,061857388
    Depreciation Qtr Cr 180136162130176107117
    Interest Qtr Cr 80107826
    Tax Qtr Cr 367331206250265221105
    Net Profit Qtr Cr 1,030895355679720759653
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 16,24713,758
    Operating Expenses Annual Cr 11,9989,725
    Operating Profit Annual in Cr 3,7933,366
    Depreciation Cr 596460
    Interest Annual Cr 2727
    Tax Annual Cr 971857
    Net Profit Annual Cr 2,5132,958
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 3,0352,773
    Cash from Investing Activity Annual Cr -2,758-2,464
    Cash from Financing Annual Activity Cr -425-427
    Net Cash Flow Annual Cr -148-117
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 24,63822,514
    Fixed Assets Annual Cr 4,3133,605
    Total Non Current Assets Annual Cr 14,22513,424
    Total Current Assets Annual Cr 13,37112,025
    Total Assets Annual Cr 27,59625,449
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 305279
    ROE Annual % 1013
    ROCE Annual % 1516
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2731
    IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
    Oper Rev Qtr Cr 6,5896,2695,6665,7305,7595,3185,224
    Operating Expenses Qtr Cr 4,9444,8354,5664,4034,5264,2324,511
    Operating Profit Qtr Cr 1,7341,4941,1741,4081,3021,143750
    Depreciation Qtr Cr 290239346272299254290
    Interest Qtr Cr 26163432261818
    Tax Qtr Cr 43837822241030326871
    Net Profit Qtr Cr 1,131996522801789686362
    IndicatorMar 2023Mar 2022
    Total Revenue Annual Cr 23,22922,044
    Operating Expenses Annual Cr 17,72617,211
    Operating Profit Annual in Cr 5,0274,553
    Depreciation Cr 1,1721,052
    Interest Annual Cr 110106
    Tax Annual Cr 1,203934
    Net Profit Annual Cr 2,8022,517
    IndicatorMar 2023Mar 2022
    Cash from Operating Activity Annual Cr 3,2383,326
    Cash from Investing Activity Annual Cr -2,389-1,872
    Cash from Financing Annual Activity Cr -958-1,600
    Net Cash Flow Annual Cr -109-146
    IndicatorMar 2023Mar 2022
    Total ShareHolders Funds Annual Cr 23,40820,842
    Fixed Assets Annual Cr 7,2707,312
    Total Non Current Assets Annual Cr 12,18812,374
    Total Current Assets Annual Cr 17,27514,728
    Total Assets Annual Cr 29,46327,101
    IndicatorMar 2023Mar 2022
    Book Value Per Share Annual Rs 294262
    ROE Annual % 1212
    ROCE Annual % 1817
    Total Debt to Total Equity Annual --
    EBDIT Annual Margin % 2422
    Invest in Cipla

    Cipla Technicals

    EMA & SMA

    Current Price
    ₹1,222.8
    17.6 (1.46%)
    pointer
    • Bullish Moving Average
    • ___
    • 15
    • Bearish Moving Average
    • ___
    • 1
    • 20 Day
    • ₹1,216.20
    • 50 Day
    • ₹1,206.64
    • 100 Day
    • ₹1,174.78
    • 200 Day
    • ₹1,122.48
    • 20 Day
    • ₹1,225.53
    • 50 Day
    • ₹1,200.01
    • 100 Day
    • ₹1,196.55
    • 200 Day
    • ₹1,069.01

    Cipla Resistance and Support

    PIVOT
    ₹1,214.94
    Resistance
    First Resistance 1,232.87
    Second Resistance 1,242.93
    Third Resistance 1,260.87
    RSI 52.11
    MFI 52.42
    MACD Single Line 3.03
    MACD 1.03
    Support
    First Resistance 1,204.87
    Second Resistance 1,186.93
    Third Resistance 1,176.87

    Cipla Delivery and Volume

    Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
    Day 1,350,526 74,386,972 55.08
    Week 1,650,520 109,396,466 66.28
    1 Month 1,870,309 94,357,106 50.45
    6 Month 1,863,361 91,267,419 48.98

    Cipla Result Highlights

    Cipla Synopsis

    NSE-Medical-Generic Drugs

    Cipla is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 15790.60 Cr. and Equity Capital is Rs. 161.43 Cr. for the Year ended 31/03/2023. Cipla Ltd. is a Public Limited Listed company incorporated on 17/08/1935 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24239MH1935PLC002380 and registration number is 002380.
    Market Cap 98,755
    Sales 16,776
    Shares in Float 54.09
    No of funds 953
    Yield 0.69
    Book Value 3.95
    U/D Vol ratio 1.3
    LTDebt / Equity
    Alpha 0.03
    Beta 0.5

    Cipla

    Owner NameSep-23Jun-23Mar-23Dec-22
    Promoters 33.47%33.47%33.55%33.61%
    Mutual Funds 16.48%15.35%15%14.09%
    Insurance Companies 5.25%6.26%4.74%4.85%
    Foreign Portfolio Investors 25.74%25.49%27.42%28.39%
    Financial Institutions/ Banks 0.04%0.01%0.11%0.11%
    Individual Investors 14.45%14.66%14.85%14.72%
    Others 4.57%4.76%4.33%4.23%

    Cipla Management

    Name Designation
    Dr. Y K Hamied Chairman
    Mr. M K Hamied Vice Chairman
    Ms. Samina Hamied Executive Vice Chairman
    Mr. Umang Vohra Managing Director & Global CEO
    Mr. S Radhakrishnan Non Exe.Non Ind.Director
    Mr. Ashok Sinha Independent Director
    Mr. P R Ramesh Independent Director
    Mr. Robert Stewart Independent Director
    Dr. Mandar Vaidya Independent Director
    Mr. Adil Zainulbhai Independent Director
    Ms. Punita Lal Independent Director

    Cipla Forecast

    Price Estimates

    2,000(9.8%)
    1,758(-3.5%)
    1,590(-12.7%)

    Other Analyst Rating

    Cipla Corporate Action

    Date Purpose Remarks
    2023-10-27 Quarterly Results
    2023-07-26 Quarterly Results
    2023-05-12 Audited Results & Final Dividend
    2023-01-25 Quarterly Results
    2022-11-04 Quarterly Results
    Date Purpose Remarks
    2023-07-21 FINAL Rs.8.50 per share(425%)Final Dividend
    2022-08-10 FINAL Rs.5.00 per share(250%)Dividend

    Cipla MF Shareholding

    Name Amount(cr)
    SBI Nifty 50 ETF 155,471
    HDFC Balanced Advantage Fund Growth 63,981
    SBI Equity Hybrid Fund Regular Payout Inc Dist cum Cap Wdrl 59,302
    ICICI Prudential Balanced Advantage Fund Growth 49,871
    Parag Parikh Flexi Cap Regular Growth 44,038

    About Cipla

    Cipla Ltd. is a pharmaceutical company in India with a strong global presence. With operations in 80 countries and 47 manufacturing facilities, it sells 1500 products in the market. The largest market of Cipla Ltd. is India, followed by Africa and North America.

    The product profile of Cipla Ltd. ranges from drugs in the respiratory, pediatric asthma, nebulisation, anti-retroviral, urology, cardiology, anti-infective, CNS, and several other illnesses and disorders. Cipla's business is divided into three units - Generics and Branded Generics, Specialty and Consumer Health. 

    The Generics and Branded Generics unit contributes around 19% of the pharmaceutical revenues in India. The division has 4,000+ partners covering the entire country and is constantly seeking to expand the product portfolio.

    The Specialty unit focuses on speciality medicines in respiratory, CNS and critical care. This unit's operations are run under Cipla Technologies LLC (CipTec) and have its headquarters in San Diego, California. 

    The Consumer Health Segment focuses on simplifying healthcare and offering simple and over-the-counter solutions to the consumers. A few brands under this business unit are Nicotex, ActivKids ImmunoBoosters, Cofsils, and UnoBiotics.

    Cipla was founded in 1935 in Mumbai as Chemical Industrial & Pharmaceutical Laboratories Ltd. by Khwaja Abdul Hamied. The name of the company was changed to Cipla in 1984. It received a major boost in 1985 when the US FDA approved its bulk drug facility. Cipla went on to launch the world's first oral iron chelator in 1995. 

    The company acquired the South African company Cipla-Medproin in 2013 and entered digital therapeutics by partnering with Wellthy Therapeutics in India and Brandmed in South Africa in 2019.

    In September 2021, Cipla Ltd. subscribed to 5% equity shares (on a fully diluted basis) of Swasth Digital Health Foundation. It is a not-for-profit organisation focused on building digital healthcare infrastructure.

    Shareholding Pattern

    A total of 230 mutual funds invest in Cipla Ltd., with a total holding of 13.91%. The number of FIIs and FPIs that have invested in it is 786, and their total holding amount to 26.64. These figures are as of March 2022.

    The top mutual funds that have invested in Cipla Ltd. are SBI ETF Nifty 50, Baroda BNP Paribas Balanced Advantage Fund Regular Growth, Mirae Asset Healthcare Fund Regular Growth, Franklin India Bluechip Fund-Growth and UTI Nifty ETF.

    Cipla FAQs

    What is Share Price of Cipla ?

    Cipla share price is ₹1,222 As on 07 December, 2023 | 19:10

    What is the Market Cap of Cipla ?

    The Market Cap of Cipla is ₹98722.8 Cr As on 07 December, 2023 | 19:10

    What is the P/E ratio of Cipla ?

    The P/E ratio of Cipla is 28.6 As on 07 December, 2023 | 19:10

    What is the PB ratio of Cipla ?

    The PB ratio of Cipla is 4.2 As on 07 December, 2023 | 19:10

    Is it the right time to invest in Cipla?

    Cipla may be the correct pick right now for investors searching for value buys of quality stocks with a longer time horizon. Cipla comes with a HOLD recommendation from the analyst. Cipla has a trailing 12-month operating revenue of INR 20,799.29 crore. Annual revenue growth of 11% is strong, the pre-tax margin of 17% is excellent, and ROE of 13% is excellent. The company has a debt-to-equity ratio of 7%, which indicates a stable balance sheet. Institutional holding has gone up in the last reported quarter is a positive sign.

    Is Cipla an Indian company?

    Cipla Limited, headquartered in Mumbai, India, is an Indian multinational pharmaceutical corporation. Cipla primarily produces drugs for the treatment of respiratory, cardiovascular, arthritis, diabetes, weight loss, and depression, as well as other medical disorders.

    Who is the CEO of Cipla?

    Umang Vohra has been the CEO of Cipla since 1 September 2016.

    What is Cipla's stock price CAGR?

    Cipla's stock price CAGR over ten years is 11%, five years is 10%, three years is 20%, and one year is 22% percent.

    How to buy Cipla Ltd. shares?

    You can easily buy the shares of Grasim Industries Ltd. by registering at 5Paisa and setting up a Demat Account in your name to start trading.

    Q2FY23

    More Information

    CIN: L67190MH2007PLC289249 | Stock Broker SEBI Regn.: INZ000010231 | SEBI RA Regn.: INH000004680 | SEBI Depository Regn.: IN DP CDSL: IN-DP-192-2016 | AMFI REGN No.: ARN-104096 | NSE Member id: 14300 | BSE Member id: 6363 | MCX Member ID: 55945 | Investment Adviser Regn No: INA000014252 | Registered Address - IIFL House, Sun Infotech Park, Road no. 16V, Plot no. B-23, MIDC, Thane Industrial Area, Waghle Estate, Thane, Maharashtra - 400604

    *Brokerage will be levied flat fee/executed order basis and not on a percentage basis. Flat fee of Rs. 10/order is available with Power Investor & Ultra Trader Packs. Investment in securities market are subject to market risk, read all related documents carefully before investing. Digital account would be opened after all procedure relating to IPV and client due diligence is completed. If sale/ purchase value of share of Rs.10/- or less, a maximum brokerage of 25 paisa per share may be collected. Brokerage will not exceed the SEBI prescribed limit.

    Compliance Officer: Ms. Namita Godbole, Email: support@5paisa.com, Support desk helpline: 8976689766

    Contact Us

    Attention Investors

    • 1. No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.
    • 2. Message from Exchange(s): Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your stock brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day. Issued in the interest of investors.
    • 3. Message from Depositories: a) Prevent Unauthorized Transactions in your demat account --> Update your mobile number with your Depository Participant. Receive alerts on your registered mobile for all debit and other important transactions in your demat account directly from CDSL on the same day issued in the interest of investors. b) KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
    ©2023, 5Paisa Capital Ltd. All Rights Reserved.
    We are ISO 27001:2013 Certified.